1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Thirty-day major adverse events and long-term follow-up
Unmatched CohortMatched Cohort
Near-Occlusion (n = 84 Patients)Control Group (n = 460 Patients)P ValueNear-Occlusion (n = 84 Patients)Control Group (n = 168 Patients)P Value
TIA during hospitalization (No.) (%)6 (7.1)12 (2.6).0456 (7.1)7 (4.2).368
A, Minor stroke during hospitalization (No.) (%)3 (3.6)5 (1.1).1113 (3.6)3 (1.8).404
B, Major stroke during hospitalization (No.) (%)1 (1.2)6 (1.3)1.0001 (1.2)4 (2.4).668
Hyperperfusion syndrome during hospitalization (No.) (%)02 (0.4)1.00000
Myocardial infarction during hospitalization (No.) (%)1 (1.2)0.1541 (1.2)0.333
Death during hospitalization (No.) (%)2 (2.4)2 (0.4).1152 (2.4)0.110
C, Minor stroke in 30-day hospitalization (No.) (%)04 (0.9)1.00002 (1.2).554
D, Major stroke in 30-day hospitalization (No.) (%)1 (1.2)2 (0.4).3961 (1.2)1 (0.6)1.000
E, Death in 30 days (including during hospitalization) (No.) (%)3 (3.6)3 (0.7).0503 (3.6)1 (0.6).109
Primary end point: A + B + C + D + E (No.) (%)7 (8.3)19 (4.1).1017 (8.3)11 (6.6).611
Re-intervention for restenosis during follow-up (No.) (%)9 (10.7)19 (4.1).0269 (10.7)6 (3.6).044
All-cause mortality during follow-up (No.) (%)33 (39.3)202 (43.9).47333 (39.3)76 (45.2).419
Cardiovascular death (No.) (%)25 (29.8)129 (28.0).79225 (29.8)53 (31.6).885
Noncardiovascular death (No.) (%)6 (7.1)64 (13.9).1106 (7.1)19 (11.3).374
Unknown death (No.) (%)2 (2.4)9 (2.0).6822 (2.4)4 (2.4)1.000
Mortality per 100 patient-years6.66.86.66.5
  • Note:—TIA indicates transient ischemic attack.